Lateral fluid percussion injury of the brain induces CCL20 inflammatory chemokine expression in rats
- 5k Downloads
Traumatic brain injury (TBI) evokes a systemic immune response including leukocyte migration into the brain and release of pro-inflammatory cytokines; however, the mechanisms underlying TBI pathogenesis and protection are poorly understood. Due to the high incidence of head trauma in the sports field, battlefield and automobile accidents identification of the molecular signals involved in TBI progression is critical for the development of novel therapeutics.
In this report, we used a rat lateral fluid percussion impact (LFPI) model of TBI to characterize neurodegeneration, apoptosis and alterations in pro-inflammatory mediators at two time points within the secondary injury phase. Brain histopathology was evaluated by fluoro-jade (FJ) staining and terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay, polymerase chain reaction (qRT PCR), enzyme linked immunosorbent assay (ELISA) and immunohistochemistry were employed to evaluate the CCL20 gene expression in different tissues.
Histological analysis of neurodegeneration by FJ staining showed mild injury in the cerebral cortex, hippocampus and thalamus. TUNEL staining confirmed the presence of apoptotic cells and CD11b+ microglia indicated initiation of an inflammatory reaction leading to secondary damage in these areas. Analysis of spleen mRNA by PCR microarray of an inflammation panel led to the identification of CCL20 as an important pro-inflammatory signal upregulated 24 h after TBI. Although, CCL20 expression was observed in spleen and thymus after 24h of TBI, it was not expressed in degenerating cortex or hippocampal neurons until 48 h after insult. Splenectomy partially but significantly decreased the CCL20 expression in brain tissues.
These results demonstrate that the systemic inflammatory reaction to TBI starts earlier than the local brain response and suggest that spleen- and/ or thymus-derived CCL20 might play a role in promoting neuronal injury and central nervous system inflammation in response to mild TBI.
KeywordsTBI LFPI CCL20 inflammation neural damage spleen cortex hippocampus
Head wounds and brain injuries following blast explosions affect more than 1.2 million Americans annually, including U.S. soldiers involved in combat operations and public safety personnel surviving terrorist attacks. It is estimated that 150-300,000 military personnel from Operation Iraqi Freedom and Operation Enduring Freedom suffered from traumatic brain injury (TBI) [1, 2, 3]
Despite the increased recognition and prevalence of TBI, the pathogenesis of TBI-induced brain injury is still poorly understood and there are currently no effective treatments. TBI is a complex process encompassing three overlapping phases: primary injury to brain tissue and cerebral vasculature by virtue of the initial impact, secondary injury including neuroinflammatory processes triggered by the primary insult, and regenerative responses including enhanced proliferation of neural progenitor cells and endothelial cells. Therapies aimed at reducing TBI injury must be focused on blocking the secondary inflammatory response or promoting regeneration and repair mechanisms.
The secondary damage is progressive, evolving from hours to days after the initial trauma, and is largely due to injury of the cerebral vasculature. Degradation of the blood brain barrier (BBB) permits extravasation of circulating neutrophils, monocytes and lymphocytes into the brain parenchyma [4, 5, 6]. Inflammatory factors released by these infiltrating immune cells as well as resident microglia can cause cell death. Also, multi-organ damage in trauma patients can lead to elevated circulatory levels of inflammatory cytokines that may contribute to the post-TBI pathogenesis of the brain . Spleen, a reservoir of immune cells, plays an important role in initiating the systemic ischemic response to stroke and neurodegeneration . Reduction in splenic mass with corresponding increase of immune cells in circulation following TBI has been observed recently by Walker et al. . Various cytokines and chemokines have been reported to be involved in TBI, including IL-1, IL-6, IL-8, IL-10, granulocyte colony-stimulating factor, tumour necrosis factor-α, FAS ligand and monocyte chemo-attractant protein 1 [7, 10] and are thought to account for the progressive injury. But, there is a paucity of mechanistic data implicating activated microglia, reactive astrocytes, or peripheral leukocytes in the release of inflammatory molecules that exacerbate TBI injury.
While profiling of inflammatory markers provides some clues regarding the source and progression of TBI pathology, it has not led to the development of a successful therapy to combat TBI-induced brain damage and its long term outcome. Therefore, identification of one or more specific molecules as unique biomarkers and therapeutic targets is of critical importance in extending experimental treatments to patients. The present study was conducted to examine the relationship between the brain response to TBI and the systemic immune response in a rat model of TBI. The LFPI model of TBI used in this study offers an excellent model of clinical contusion without skull fracture [11, 12], expressing the features of the primary injury including the disruption of the BBB, secondary injury and diffuse axonal injury . In this study, we characterized the injury caused by LFPI in the rat and identified CCL20 as both a peripheral and local immune signal in the pathogenesis of TBI.
All animal procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals following a protocol approved by the Institutional Animal Care and Use Committee at the University of South Florida. Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250 to 300 g were housed in a climate-controlled room with water and laboratory chow available ad libitum. A total of 33 animals were used in this study.
Induction of Lateral Fluid Percussion Injury (LFPI)
Animals were anesthetized using a mixture of ketamine (90 mg/kg)/xylazine (10 mg/kg) (IP). To deliver LFPI, a 1 mm diameter craniotomy was performed centered at 2 mm lateral and 2.3 mm caudal to the bregma on the right side of the midline. A female luer-lock hub was implanted at the craniotomy site and secured with dental cement. The FPI device was then fastened to the luer-lock. All tubing was checked to ensure that no air bubbles had been introduced, after which a mild impact ranging from 2.0-2.2 atm. was administered . Impact pressures were measured using a transducer attached to the point of impact on the fluid percussive device. The luer-lock was then detached, the craniotomy hole was sealed with bone wax and the scalp was sutured. Ketoprofen (5 mg/kg) was administered to minimize postsurgical pain and discomfort. Rats were then replaced in their home cages and allowed to recover for 24-48 h prior to subsequent experiments. Animals were excluded from further tests if the impact did not register between 2.0 and 2.2 atm. or if the dura was disturbed during the craniotomy prior to impact. In sham (control) animals, craniotomy was performed at the same coordinates as the TBI animals but no impact was delivered.
To remove the spleen from the anesthetized rat a cranial-caudal incision was made lateral to the spine with the cranial terminus of the incision just behind the left rib cage. A small incision was made on the exposed muscle layer to access the spleen. The spleen was then pulled out through the incision, the splenic blood vessels were tied with 4.0 silk sutures and the spleen was removed by transecting the blood vessels distal to the ligature. The attached pancreatic tissues were detached from the spleen by blunt dissection and returned to the abdominal cavity before removal of the spleen. The muscle and skin incisions were sutured and the animals were allowed to survive for 24 or 48 hours.
Animals were deeply anesthetized with ketamine (75 mg/kg) and xylazine (7.5 mg/kg) 24 or 48 hours after TBI. Thymuses and spleens were removed and immediately snap frozen on dry ice. Animals were then perfused with 0.9% saline followed by 4% paraformaldehyde in phosphate buffer (pH 7.4). The brains were harvested, post-fixed in 2% paraformaldehyde and saturated with increasing sucrose concentrations (20% to 30%) in phosphate-buffered saline (PBS, pH 7.4). Brains were then frozen, sectioned coronally at 30 μm thickness using a cryostat, thaw-mounted onto glass slides and stored at -20°C prior to staining. In the initial studies 80% of the injured neurons were found in the brain region between 3.5 and 5.5 mm caudal to the bregma. Therefore, for all subsequent staining experiments, three sections from each brain corresponding to 3.5, 4.5, and 5.5 mm caudal to the bregma were selected for analysis.
RNA extraction, purification and cDNA synthesis
Total RNA was extracted from 50 mg of frozen spleen tissue using TRIZOL reagent (Invitrogen, Carlsbad, CA). Briefly, the samples were homogenized with 1 ml of TRIZOL, incubated at room temperature for 5 minutes and phase-separated by chloroform. Total RNA was precipitated by isopropyl alcohol, collected by centrifugation and purified using an RNeasy mini kit (Qiagen, Valencia, CA). The RNA concentration and purity was determined by spectrophotometry at 260/280 nm and 260/230 nm. First strand cDNA was synthesized from the isolated RNA using the Superscript III system (Invitrogen).
mRNA SuperArray analysis
A panel of proinflammatory cytokines and chemokines and their receptors was analyzed using a SYBR green-optimized primer assay (RT2 Prolifer PCR Array) from SA bioscience (Frederick, MD). Briefly, cDNA was synthesized from fresh frozen spleens as stated above. cDNA was mixed with the RT2 qPCR master mix and the mixture was aliquoted across the PCR array. The PCR was done in a CFX96 Real-Time C1000 thermcycler (BioRad) for 5 min at 65C, 50 min at 50C and 5 min at 85C. Control gene expression was normalized and target gene expression was expressed as fold increase or decrease compared to control. PCR data were analyzed using the SA Bioscience Excel program.
Enzyme-linked immunosorbent assay (ELISA) for CCL20
Spleen tissue lysates were prepared from 5 mg of fresh frozen tissue using protein lysis buffer containing NP-40. CCL20 was estimated by ELISA using the DuoSet ELISA Development kit for CCL20 from R & D systems (Minneapolis, MN). Briefly, 96 well sterile ELISA microplates were coated with anti-rat CCL20α antibody overnight at room temperature. Next day, the plates were washed and blocked with bovine serum albumin (BSA). Plates were incubated sequentially with standards or samples for 2 h, detection antibody (biotinylated goat anti-rat CCL20α antibody) for 2 h, streptavidin-HRP for 20 minutes and substrate solution (1:1 mixture of H2O2 and tetramethylbenzidine) for 20 minutes. Reactions were stopped with 2N H2SO4. All incubations were performed at room temperature and the microplate was thoroughly washed after each incubation. The absorbance of each well was determined at 450 nm using a Synergy H4 Hybrid reader (BioTek). Total protein concentrations from the same samples were determined by BCA protein assay (Pierce). CCL20 was expressed as pg per μg of total protein in the tissue.
Fluoro-Jade (Histochem, Jefferson, AR) staining was performed to label degenerating neurons. This method was adapted from that originally developed by Schmued et at  and subsequently detailed by Duckworth . Thaw-mounted sections were placed in 100% ethanol for 3 minutes followed by 70% ethanol and deionized water for 1 minute each. Sections were then oxidized using a 0.06% KMnO4 solution for 15 minutes followed by thee rinses in ddH2O for 1 minute each. Sections were then stained in a 0.001% solution of Fluoro-Jade in 0.1% acetic acid for 30 min. Slides were rinsed, dried at 45°C for 20 min, cleared with xylene, and cover-slipped using DPX mounting medium (Electron Microscopy Sciences, Ft. Washington, PA).
Nuclear DNA fragmentation, a marker of apoptotic cells was measured using the DeadEnd Fluorimetric TUNEL system (Promega, Madison, WI). Fixed cryosections (30μ thick) were permeabilized with 20 μg/ml proteinase K at room temperature for 8 minutes followed by 4% PFA in PBS for 5 minutes. The sections were washed in PBS and equilibrated with 200 mM potassium cacodylate, pH 6.6; 25 mM Tris-HCl, pH 6.6; 0.2 mM DTT; 0.25 mg/ml BSA and 2.5 cobalt chloride (equilibration buffer) for 10 minutes at room temperature. The sections were then incubated at 37°C for 1 hour with incubation buffer containing equilibration buffer, nucleotide mix and rTdT enzyme mix, covered with plastic cover slip and placed away from exposure to light. The cover slips were removed and the reactions were stopped with 2X SSC. The sections were then washed with PBS and mounted with VectaShield mounting medium containing DAPI. The green fluorescence of fluorescein-12-dUTP was detected in the blue background of DAPI under the fluorescence microscope. Images were taken and apoptotic nuclei were quantified using the Image J quantitation program.
Spleen, thymus or brain tissue sections were washed with PBS for 5 min, incubated in 3% hydrogen peroxide for 20 min and washed 3 times in PBS. They were then heated in antigen unmasking solution (1:100; Vector Laboratories Inc., Burlingame, CA) for 20 min at 90°C, incubated for 1 h in permeabilization buffer (10% goat serum, 0.1% Triton X-100 in PBS) and incubated overnight at 4°C with either rabbit anti-CCL20 primary antibody (1:1000) or mouse monoclonal anti-CD11b antibody (1:400) (Abcam, Cambridge, MA) in antibody solution (5% goat serum, 0.05% Triton X-100 in PBS). The following day, sections were washed with PBS and incubated 1 h at room temperature with secondary antibody (biotinylated goat anti-rabbit, 1:400, Vector Laboratories Inc., Burlingame, Ca or Alexafluor 594 conjugated antimouse antibody, 1:50 or DyLight 594 conjugated antirabbit antibody, 1:50) in antibody solution. Sections incubated with biotinylated antirabbit antibody were then washed in PBS, incubated in avidin-biotin complex mixture (ABC,1:100; Vector Laboratories Inc, Burlingame, Ca) for 1 h, washed again and visualized using DAB/peroxide solution (Vector Laboratories Inc). After three washes, sections were dried, dehydrated with increasing concentrations of ethanol (70%, 95%, 100%), cleared with xylene and cover-slipped with Vectamount mounting medium. Sections incubated with mouse anti-CD11b antibody followed by alexafluor 594-conjugated antimouse antibody were washed three times with PBS and used for double staining with IB4. Some of the anti-CCL20 antibodies followed by DyLight 594-conjugated antirabbit antibody treated sections were incubated with Alexa fluor 488-conjugated mouse antineuronal nuclei (NeuN) monoclonal antibody (1:100; Millipore, Temecula, CA) 3 hours at room temperature, washed with PBS, dried and cover slipped with vectamount mounting medium with DAPI.
CCL20 - Fluoro-Jade double staining
Slide mounted sections were washed in PBS and CCl20 immunostaining was performed as described above and developed with DyLight 594 conjugated anti rabbit antibody. Sections were then incubated in acidic 0.0001% FJ solution for 20 min on shaker. Slides were washed, dried and cover slipped with Vecta Shield mounting medium.
Isolectin IB4 histochemistry
Brain sections were washed with modified PBS (PBS with 0.5mM CaCl2, pH 7.2) and permeabilized with buffer containing 10% goat serum, 3% lysine, 0.3% triton X-100 in modified PBS for 1 hour at room temperature. Brain sections already immunostained were transferred to modified PBS. Sections were then incubated overnight at 4°C with 5 μg/ml Alexa 488-conjugated isolectin IB4 (Molecular Probes) dissolved in modified PBS with 0.3% triton X-100 and 2% goat serum. Stained sections were washed with modified PBS, mounted with Vecta-Shield mounting medium with DAPI and viewed with an Olympus IX71 fluorescent microscope using the FITC filter. Images were taken using the Olympus DP70 imaging system and IB4-positive cells were quantified using the Image J quantitation program.
Image analysis and quantitation
All quantitation was performed using the NIH Image J software. For immunohistochemical analysis, images were acquired using an Olympus IX71 microscope controlled by DP70 manager software (Olympus America Inc., Melville, NY). Photomicrographs captured at 200x magnification with an Olympus DP70 camera were used for quantification. Images were taken at the same exposure and digital gain settings for a given magnification to minimize differential background intensity or false-positive immunoreactivity across sections. The channels of the RGB images were split and the green channel was used for quantitation of the FJ, IB4 and TUNEL staining images. The CCL20 images were converted to gray-scale before quantitation. The single channel or gray-scale images were then adjusted for brightness and contrast to exclude noise pixels. The images were also adjusted for the threshold to highlight all the positive cells to be counted and a binary version of the image was created with pixel intensities 0 and 255. Particle size was adjusted to exclude the small noise pixels from the count. Circularity was adjusted to between 0 and 1 to discard any cell fragments, processes or tissue aggregates resulting in false labelling from the quantitation. The same specifications were used for all sections. Cell counts of sections from 3.5, 4.5 and 5.5 mm caudal to the bregma were summed to represent the number of positive cells from each brain. The results for the FJ, TUNEL, IB4 and CCL20 immunoreactivity were expressed as mean number of positive cells ± S.E.M. CCL20 immunoreactivity of the thymus or the spleen was expressed as mean area of immunoreactivity ± S.E.M.
All data are presented as mean ± S.E.M. Statistical significance was evaluated by one-way ANOVA with Bonferroni's post-hoc test. A p value of less than 0.05 was considered statistically significant for all comparisons.
Regional distribution of neurodegeneration after TBI
Mild TBI-induced internucleosomal DNA fragmentation in the cortex and hippocampus
Microglia are activated in the brain following mild TBI
CCL20 is identified as a major inflammatory gene expressed in the spleen and thymus following TBI
CCL20 is expressed in the brain following TBI-induced neurodegeneration
Splenectomy attenuates TBI-induced neurodegeneration and CCL20 expression in the cortex
Mild TBI comprises almost 80% of clinical TBI. Despite continuing research and accumulated knowledge, an effective treatment for mild TBI is still not available. In the present study, we have adopted the LFPI model of TBI originally characterized by McIntosh et. al.  to develop a methodology that results in quantifiable reproducible injury. Because pressure pulses within the range used here (2.0-2.2 atm.) are generally considered to reflect mild injury in the rat model , this paradigm is particularly attractive in that it lends relevance to the clinical population suffering from mild injury. However, conflicting data in the literature regarding the regional and temporal injury distribution prompted us to conduct a comprehensive investigation throughout the brain to determine where approximately 80% of the injury is found at 24 and 48 h post-impact. These endpoints were selected because they represent a delayed window within the secondary injury phase that can be targeted by novel therapeutics.
Consistent with previous studies using the LFPI [20, 18, 21] FJ and TUNEL staining in this study showed that the predominant areas of neurodegeneration and apoptosis include the cerebral cortex, hippocampus, and thalamus. In a previous study using similar TBI methodology, Sato et al.  showed Fluoro-Jade and TUNEL staining that persisted from 3 hours to 7 days and included cerebellar damage in addition to damage in those regions identified here. Furthermore, we have demonstrated that LFPI-induced neurodegeneration paralleled with increase in activated microglia in the injured brain. Also, in accordance with the observation of Stahel et al., the dying neurons showed characteristics of both necrosis and apoptosis . These observations indicate that substantial inflammation takes place in the brain parenchyma in response to mild LFPI in this study.
The nature and progression of TBI-induced brain pathology limits the goals of treatment to either blocking the secondary injury phase or facilitating plasticity and repair at some point after the initial impact. The secondary phase is largely a result of the migration of activated microglia towards the site of injury, secreting toxic cytokines and oxygen radicals and thereby causing further neuronal damage [13, 23, 24]. Lunemann et. al.  have shown that following the formation of a brain lesion, microglia invade the damaged brain tissue after maturing and becoming activated by producing macrophage activating factor (MAF) in a CD11b-positive pathway. In agreement with this finding, we have also observed that within 24 h of initial damage the brain parenchyma is invaded by activated microglial cells. This indicates that an active inflammatory reaction is generated locally in the brain as early as 24 hours after injury.
The spleen is a reservoir of peripheral macrophages and other immune cells in the body, and it is now well known that splenic signalling contributes to injury of various tissues after ischemic insult. For example, splenectomy prior to insult protects both the liver  and brain  from ischemic damage. In a recent study, Li et al. have shown that splenectomy immediately after TBI in rats decreased proinflammatory cytokine production and mortality rate and improved cognitive function. In our study, we observed that splenectomy immediately after induction of TBI attenuated TBI-induced neurodegeneration and CCL20 expression in the brain. Although it is not clear how this spleen-brain interaction takes place, Lee et al.  suggested that vagal nerve stimulation may reduce immune cell infiltration and consequent decrease in brain inflammation and edema while Stewart and McKenzie  suggested a role of sympathetic stimulation in causing the release of immune cells from spleen and subsequent infiltration into the brain tissues. Regardless of the neural mechanism, removal of the spleen immediately after the insult would remove the largest pool of immune cells, resulting in decreased infiltration and consequent neuroinflammation. Our study clearly shows that reduction in the splenic immune cell population reduced neuronal damage and CCL20 production.
Interestingly, CCL20 is a unique chemokine known to interact specifically with CC chemokine receptor 6 (CCR6) and induce chemotaxis of dendritic cells, T cells and B cells , all of which reside in the spleen and have the potential to promote neuroinflammation. Several lines of evidence support this hypothesis. Ohta et al.  have shown that CCL20 was up-regulated under normothermic conditions in a rat middle cerebral artery occlusion (MCAO) model. CCL20 is also expressed in inflamed epithelial cells  and in the synovial tissues of rheumatoid arthritis patients [32, 33], while up-regulation of CCL20 along with other cytokines has been observed in human subjects one day after severe traumatic brain injury . Furthermore, a recent study identified CCL20 as a dual-acting chemokine with the potential for inhibiting immune reactions and more importantly in attracting inflammatory effectors and activators . Although a great deal of investigation has recently been done to elucidate the relationship between brain trauma and the immune system, very little is known about the function of the thymus after brain trauma. Since the thymus is the major source of mature circulating T cells, CCL20 expression in the thymus as observed in this study seems significant, although further investigation is needed to identify the specific function of thymus after TBI in adult rats.
Because CCL20-CCR6 signalling is now known to facilitate the immune response in pathological circumstances, data from the present study demonstrating up-regulated CCL20 in spleen and thymus 24 h post-LFPI likely reflects the initiation or persistence of a systemic signal that drives neural inflammation and cell death. Mouse models of autoimmune encephalomyelitis (EAE) have provided some evidence that T cells may be targeted by the splenic signal. A recent knockout study demonstrated that CCR6 modulates the infiltration of T cells into the brains of EAE-infected mice, although reduced infiltration of Treg in CCR6-/- mice was associated with increased neurological damage . Despite evidence of a protective role for CCR6 activation, CCL20 signaling through CCR6 on Th1 or Th17 cells, rather than Treg cells, would be expected to promote inflammation. CCR6 is constitutively expressed in the choroid plexus of mouse and human and there are data showing that the binding of CCL20 to CCR6 on Th17 cells is critical for T cell infiltration into the CNS through the choroid plexus . Indeed, T cells are well known for infiltrating the brain in neural injury models characterized by a compromised BBB. Because BBB degradation is also a critical component of TBI [19, 23], peripheral CCL20 signalling may be an important initiator of T cell chemotaxis and extravasation into the brain parenchyma.
Data presented in this report also show that CCL20 was not expressed in degenerating cortical or hippocampal cell layers until 48 h after the impact. This raises the question of why cortical and hippocampal neurons expressed CCL20 at 48 h, which is 24 h after the systemic expression of the same chemokine and the neurodegeneration in the same areas of the injured brain. Although CCL20 is produced by astrocytes in response to bacterial infections  and EAE , to the best of our knowledge, ours is the first report to demonstrate neuronal expression of CCL20. One possibility is that cellular injury induces expression of CCL20 as a signal for peripheral or local immune cell recruitment to the injured site. If so, it is also likely that the neuronal cells that expressed CCL20 were in the immediate vicinity of those cells undergoing neurodegeneration. However, another possibility is that neuronal CCL20 expression is a 'tombstone' marker in cells that are beyond repair and need to be removed from the surrounding viable tissues. This latter explanation is supported by the pyknotic morphology that was observed in CCL20-expressing neurons, as well as the fact that the areas surrounding the cell bodies appeared to be devoid of tissue. The morphological analysis, anatomical localization and colocalization with FJ and NeuN protein of CCL20-positive cells strongly suggest that neurons represent the predominant cell type expressing this chemokine following TBI. Preliminary observations from this laboratory indicate downregulation of peroxysome proliferator-activated receptor γ (PPARγ) in neuronal cells (data not shown) after TBI; however, a causal role of PPARγ in regulating CCL20 signalling and/or expression in these cells remains to be established.
While results here demonstrate a link between CCL20 expression and LFPI-induced injury and indicate involvement of peripheral immune organs like the spleen in this response, further experiments are required to define the precise mechanisms by which CCL20 signalling contributes to cell death and the exact role played by spleen and thymus in inducing neuronal death. Furthermore, if CCL20 exerts direct actions on neurons, the 11 kDa protein could easily enter the CNS from the systemic circulation and promote injury even in the absence of peripheral leukocyte recruitment. If this latter scenario is the case, plasma CCL20 levels could be utilized as an important biomarker indicating the presence and severity of TBI.
This study identified CCL20 as a potential novel target for anti-inflammatory therapeutic intervention. Data from this study clearly showed that LFPI-induced brain injury evoked an inflammatory reaction in the injured brain and attracted a population of activated microglia resulting in further damage of the brain. The fact that CCL20 expression is elevated in the spleen and thymus prior to its appearance in the brain, and that brain CCL20 expression is decreased in splenectomised rats provide evidence that a peripheral CCL20 signal mediates the neuropathological response to TBI. These results suggest that CCL20 plays an important role in neuroinflammation in the brain after TBI, and that peripheral CCL20 signalling promotes the secondary phase of neural injury. Future studies investigating an extended time course encompassing hours to weeks after LFPI will be critical in determining the tissue- and cell-specific origins, mechanisms, and overall effects of CCL20 signalling on TBI.
This work is supported by a VA career scientist award to Shyam Mohapatra, a USF Health development grant to Subhra Mohapatra and 5R21NS060907 to Keith Pennypacker. We would like to acknowledge Xiaoyuan Kong, Jordan Heft and Sowndharya Rajavel for technical assistance and James Musso (III) for assistance in initial experiments.
- 3.Macgregor AJ, Dougherty AL, Galarneau MR: Injury-Specific Correlates of Combat-Related Traumatic Brain Injury in Operation Iraqi Freedom. J Head Trauma Rehabil. 2010Google Scholar
- 18.Li M, Li F, Luo C, Shan Y, Zhang L, Qian Z, Zhu G, Lin J, Feng H: Immediate Splenectomy Decreases Mortality and Improves Cognitive Function of Rats After Severe Traumatic Brain Injury. J Trauma. 2011Google Scholar
- 22.Stahel PF, Shohami E, Younis FM, Kariya K, Otto VI, Lenzlinger PM, Grosjean MB, Eugster HP, Trentz O, Kossmann T, Morganti-Kossmann MC: Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. J Cereb Blood Flow Metab. 2000, 20: 369-380.CrossRefPubMedGoogle Scholar
- 31.Dieu-Nosjean MC, Massacrier C, Homey B, Vanbervliet B, Pin JJ, Vicari A, Lebecque S, Dezutter-Dambuyant C, Schmitt D, Zlotnik A, Caux C: Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med. 2000, 192: 705-718. 10.1084/jem.192.5.705.PubMedCentralCrossRefPubMedGoogle Scholar
- 33.Matsui T, Akahoshi T, Namai R, Hashimoto A, Kurihara Y, Rana M, Nishimura A, Endo H, Kitasato H, Kawai S, et al: Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin Exp Immunol. 2001, 125: 155-161. 10.1046/j.1365-2249.2001.01542.x.PubMedCentralCrossRefPubMedGoogle Scholar
- 34.Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ: The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab. 2010Google Scholar
- 35.Comerford I, Bunting M, Fenix K, Haylock-Jacobs S, Litchfield W, Harata-Lee Y, Turvey M, Brazzatti J, Gregor C, Nguyen P, et al: An immune paradox: how can the same chemokine axis regulate both immune tolerance and activation?: CCR6/CCL20: a chemokine axis balancing immunological tolerance and inflammation in autoimmune disease. Bioessays. 2010, 32: 1067-1076. 10.1002/bies.201000063.CrossRefPubMedGoogle Scholar
- 37.Reboldi A, Coisne C, Baumjohann D, Benvenuto F, Bottinelli D, Lira S, Uccelli A, Lanzavecchia A, Engelhardt B, Sallusto F: C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009, 10: 514-523.CrossRefPubMedGoogle Scholar
- 39.Ambrosini E, Columba-Cabezas S, Serafini B, Muscella A, Aloisi F: Astrocytes are the major intracerebral source of macrophage inflammatory protein-3alpha/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia. 2003, 41: 290-300. 10.1002/glia.10193.CrossRefPubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.